NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026

NextCure, Inc.

2025-Q3 EPS reported -$18.84

Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.
Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.
SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.
LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.
$12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.